One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Shineco, Inc. logo
Shineco, Inc. TYHT

Shineco, Inc. Balance Sheet 2020-2011 | TYHT

Brief overview of Shineco, Inc.'s financial position

The balance sheet is assessed across five available annual reports spanning 2016 to 2020.

The balance sheet expanded from $57 million to $79.1 million. Growth of +38.6% and CAGR of 8.5% look measured and sustainable.

Funding shifted toward liabilities: they gained +83.7%, compared with +38.6% for assets.

Negative net debt of -$29.6 million means cash holdings are larger than debt obligations.

Retained earnings are $44.3 million versus $34.1 million initially. The direction shows how results contributed to equity.

Overall assessment

Shineco, Inc.'s financial position is more positive than negative: the funding mix is workable, although the cushion is not unlimited.

Annual Balance Sheet Shineco, Inc.

2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-29.6 M -32.9 M -29.2 M -20.5 M -15.4 M -2.67 M -420 K 2.04 M -8.93 M -

Long Term Debt

402 K - - - 3.86 M - - - - -

Total Non Current Liabilities

2.42 M 1.73 M 1.75 M 1.09 M 955 K 848 K 690 K 580 K 420 K -

Total Current Liabilities

11.3 M 10.5 M 9.53 M 5.03 M 6.54 M 5.92 M 3.76 M 5.79 M 11 M -

Total Liabilities

13.8 M 12.2 M 11.3 M 6.12 M 7.49 M 6.77 M 4.45 M 6.37 M 11.4 M -

Deferred Revenue

- - 17.5 K 5.44 K 9.6 K - - - - -

Retained Earnings

44.3 M 50.9 M 50.1 M 42.5 M 34.1 M 25.9 M 18.7 M 10.8 M 5.01 M -

Total Assets

79.1 M 83.7 M 83.1 M 68.3 M 57 M 52.1 M 42.2 M 30.6 M 29.3 M -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Shineco, Inc., providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
SIGA Technologies SIGA Technologies
SIGA
$ 3.12 4.55 % $ 223 M usaUSA
Sage Therapeutics Sage Therapeutics
SAGE
- - $ 527 M usaUSA
Taro Pharmaceutical Industries Ltd. Taro Pharmaceutical Industries Ltd.
TARO
- - $ 1.62 B israelIsrael
Sol-Gel Technologies Ltd. Sol-Gel Technologies Ltd.
SLGL
$ 61.62 -2.21 % $ 172 M israelIsrael
SELLAS Life Sciences Group SELLAS Life Sciences Group
SLS
$ 8.41 6.73 % $ 917 M usaUSA
Summit Therapeutics Summit Therapeutics
SMMT
$ 16.34 15.15 % $ 12.2 B britainBritain
Cabaletta Bio Cabaletta Bio
CABA
$ 1.3 1.17 % $ 131 M usaUSA
Syndax Pharmaceuticals Syndax Pharmaceuticals
SNDX
$ 9.53 1.39 % $ 826 M usaUSA
Sanofi Sanofi
SNY
$ 47.06 0.32 % $ 57.4 B franceFrance
Forma Therapeutics Holdings Forma Therapeutics Holdings
FMTX
- - $ 958 M usaUSA
Blueprint Medicines Corporation Blueprint Medicines Corporation
BPMC
- - $ 8.14 B usaUSA
Horizon Therapeutics Public Limited Company Horizon Therapeutics Public Limited Company
HZNP
- - $ 26.6 B irlandaIrlanda
Sarepta Therapeutics Sarepta Therapeutics
SRPT
$ 17.8 0.68 % $ 1.78 B usaUSA
Paratek Pharmaceuticals Paratek Pharmaceuticals
PRTK
- - $ 121 M usaUSA
China SXT Pharmaceuticals China SXT Pharmaceuticals
SXTC
$ 2.84 -3.07 % $ 1.93 M chinaChina
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
TAK
$ 21.02 -0.92 % $ 33.2 B japanJapan
Tarsus Pharmaceuticals Tarsus Pharmaceuticals
TARS
$ 68.11 0.87 % $ 2.85 B usaUSA
ASLAN Pharmaceuticals Limited ASLAN Pharmaceuticals Limited
ASLN
- -14.27 % $ 1.7 M singaporeSingapore
Bio-Techne Corporation Bio-Techne Corporation
TECH
$ 72.78 0.17 % $ 11.4 B usaUSA
Teva Pharmaceutical Industries Limited Teva Pharmaceutical Industries Limited
TEVA
$ 42.32 1.33 % $ 48.5 B israelIsrael
RedHill Biopharma Ltd. RedHill Biopharma Ltd.
RDHL
$ 0.43 0.45 % $ 5.3 B israelIsrael
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Unity Biotechnology Unity Biotechnology
UBX
- -33.41 % $ 3.37 M usaUSA
iTeos Therapeutics iTeos Therapeutics
ITOS
- - $ 411 M usaUSA
Shattuck Labs Shattuck Labs
STTK
$ 4.59 2.78 % $ 319 M usaUSA
Seelos Therapeutics Seelos Therapeutics
SEEL
- -47.76 % $ 6.27 M usaUSA
Evogene Ltd. Evogene Ltd.
EVGN
$ 0.28 -16.14 % $ 2.2 M israelIsrael
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Protara Therapeutics Protara Therapeutics
TARA
$ 2.33 9.15 % $ 99.8 M usaUSA
Trevi Therapeutics Trevi Therapeutics
TRVI
$ 14.33 11.87 % $ 1.93 B usaUSA
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.
GLMD
$ 4.63 21.05 % $ 20 M israelIsrael
Fennec Pharmaceuticals Fennec Pharmaceuticals
FENC
$ 9.79 4.26 % $ 280 M usaUSA
Kiromic BioPharma Kiromic BioPharma
KRBP
- 6.61 % $ 3.08 M usaUSA
CNS Pharmaceuticals CNS Pharmaceuticals
CNSP
$ 3.92 -2.24 % $ 1.74 M usaUSA
Calithera Biosciences Calithera Biosciences
CALA
- -10.95 % $ 876 K usaUSA
United Therapeutics Corporation United Therapeutics Corporation
UTHR
$ 562.14 -0.63 % $ 24.9 B usaUSA
Vericel Corporation Vericel Corporation
VCEL
$ 54.56 5.36 % $ 2.75 B usaUSA
Veracyte Veracyte
VCYT
$ 24.1 0.42 % $ 1.89 B usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Fulcrum Therapeutics Fulcrum Therapeutics
FULC
$ 3.72 0.95 % $ 236 M usaUSA
Molecular Templates Molecular Templates
MTEM
- -23.43 % $ 495 K usaUSA
Vanda Pharmaceuticals Vanda Pharmaceuticals
VNDA
$ 3.82 6.27 % $ 225 M usaUSA
Verrica Pharmaceuticals Verrica Pharmaceuticals
VRCA
$ 3.22 4.21 % $ 34.3 M usaUSA
Viridian Therapeutics Viridian Therapeutics
VRDN
$ 28.47 -0.28 % $ 2.9 B usaUSA
BioXcel Therapeutics BioXcel Therapeutics
BTAI
$ 0.07 9.81 % $ 855 K usaUSA
VistaGen Therapeutics VistaGen Therapeutics
VTGN
$ 0.17 3.45 % $ 6.47 M usaUSA
Voyager Therapeutics Voyager Therapeutics
VYGR
$ 1.86 8.14 % $ 109 M usaUSA
CohBar CohBar
CWBR
- -15.44 % $ 2.2 M usaUSA
NeuBase Therapeutics NeuBase Therapeutics
NBSE
- -1.56 % $ 12.3 M usaUSA
Gossamer Bio Gossamer Bio
GOSS
$ 9.77 3.72 % $ 2.23 B usaUSA